New Tuberculosis treatment could save millions of lives
World-leading scientists from the Infection and Global Health Division reveal a new Tuberculosis (TB) drug that will shorten the treatment of the disease by up to 2 months, potentially saving millions of lives.
Dr Muge Cevik, a clinical academic in infectious diseases and medical virology delivers the results of the worldwide TB Alliance’s SimpliciTB clinical trial at the 30th annual Conference on Retroviruses and Opportunistic Infections (CROI) conference in Seattle on Monday 20 February. The Conference brings together the most respected infectious disease healthcare professionals and scientists from around the globe to discuss human retroviruses and other relevant infections such as TB and SARS-CoV-2 (Covid-19), CROI is one of the world’s most prestigious congresses in this field.
For full details of the University Press release and more on the study, please see link below: